Navigation Links
Vascular Designs, Inc. Receives CE Mark Approval for Its IsoFlow™ Infusion Catheter to Target Cancerous Tumors
Date:11/14/2011

SAN JOSE, Calif., Nov. 14, 2011 /PRNewswire/ -- Vascular Designs, Inc., a medical device manufacturing company, today announced that its IsoFlow™ Infusion Catheter has received CE Mark approval for use in Europe and Canada. The IsoFlow™ Infusion Catheter enables targeted sideways perfusion, allowing physicians to precisely target and isolate areas within the body where the infused drugs are delivered. With IsoFlow™ Infusion Catheter's unique design, medications can be delivered into areas that could not previously be treated directly, for instance, a cancerous tumor. The device also facilitates the LACE™ (Lateral Arterial Chemo Embolization) procedure.

(Logo: http://photos.prnewswire.com/prnh/20111114/SF06426LOGO)

"CE Mark approval is an important confirmation of the substantial benefits that patients will receive from targeted treatment of cancerous tumors," said Robert Goldman, CEO of Vascular Designs, Inc. and creator of the IsoFlow Infusion Catheter. "Directing treatment to specific locations increases the number of treatment options allowing better access to tumors and may reduce the discomfort to patients associated with the systemic application of chemotherapy."

About Vascular Designs, Inc.

Vascular Designs, Inc. is a medical device company located in San Jose, California. Founder Robert Goldman developed the idea behind Vascular Designs and its innovative IsoFlow™ Infusion Catheter. His personal experience of watching loved ones suffer from, and succumb to cancer, had a profound influence on the creation of IsoFlow.

With the IsoFlow Infusion Catheter's unique design, medications can be pushed into areas that could not previously be treated directly. According to numerous studies, this type of approach to delivery can increase drug concentrations at targeted sites while reducing systemic exposure, potentially improving treatment outcomes.

The IsoFlow Infusion Catheter is in use in hospitals throughout the United States.

For more information on Vascular Designs, Inc., please visit www.vasculardesigns.com.

To view an animation illustrating the IsoFlow Infusion Catheter in action and other press materials, please visit http://www.vasculardesigns.com/news.htm.

Media Contact: Dan Orloff, Orloff Williams Partners, San Jose, 408-202-3188, dorloff@orloffwilliams.com


'/>"/>
SOURCE Vascular Designs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
2. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
3. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
4. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
5. Cardiologists Tackle Next Frontier in Cardiovascular Disease
6. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
7. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
8. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... Tuesday, June 13, 2017, in Rancho Palos Verdes, ... chief executive officer, is scheduled to present at 3:20 p.m. ... accessed at http://ir.hill-rom.com/events.cfm . A recorded replay will be ... September 13, 2017. ...
(Date:5/29/2017)... May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... which enables the functional selection of stem cells, today ... the first quarter ended March 31 st , 2017. ... accomplishments in the first quarter of 2017," said Dr. ... we announced the treatment of the first blood cancer ...
(Date:5/26/2017)... BARBARA, Calif. , May 25, 2017  In ... United States , Direct Relief is working with ... overdose-reversing Naloxone available at no cost to community health ... other nonprofit providers nationwide. "Pfizer has ... access to medicines and ensuring patient safety through educational ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the ... are currently accepting new patients at their practice for these custom clear aligners. These ... is why they offer the latest in modern dental techniques to ensure that all ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage (UA), a multi-channel retailer ... designed to create tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle ... twill. , With trendy looks hitting the medical community, UA Flex is for the ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... bedside, would like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN ... whose insight and expertise in healthcare will provide invaluable direction for the company,” ...
(Date:6/19/2017)... New York, NY (PRWEB) , ... June 19, 2017 , ... ... and this year, it’s going to be a humdinger. A warm winter and wet ... devour summer wedding guests. “No one wants to be swatting away pesky mosquitoes when ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... nonprofit community, announces the general availability of several new and improved features to ... integration with United Way iGuide data in support of national campaigns. The ...
Breaking Medicine News(10 mins):